Tumoricidal and antimicrobial compositions and methods
AssigneeImmunityBio, Inc.
InventorsHans G. Klingemann, Barry J. Simon
Life of this patent
Estimating the term…
Abstract
Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
Claims21
-10. (canceled)
A production intermediate for a cell-based product, comprising:
- a plurality of NK-92 cells in a culture medium comprising a cytokine;
- wherein the NK-92 cells are a subpopulation of wild type NK-92 cells or modified NK-92 cells;
- wherein the subpopulation of wild type NK-92 cells or modified NK-92 cells produces cytotoxic exosomes when grown in the culture medium;
- and
- wherein the culture medium comprises exosomes and/or microvesicles that were produced by the subpopulation of wild type NK-92 cells or modified NK-92 cells in the culture medium.
The intermediate of claim 1, wherein the cytokine is IL-2, wherein the medium is a serum-free medium, and/or wherein the medium is supplemented with L-asparagine, L-glutamine, L-serine, interferon gamma, and/or IL-15.
The intermediate of claim 1, wherein the subpopulation of the wild type NK-92 cells or the modified NK-92 cells express different surface markers or proteins as compared to NK-92 cells having ATCC deposit number CRL-2407.
The intermediate of claim 1, wherein the subpopulation of the wild type NK-92 cells or the modified NK-92 cells are isolated.
The intermediate of claim 1, wherein the subpopulation of the wild type NK-92 cells or the modified NK-92 cells expresses an Fc receptor selected from the group consisting of an Fcγ receptor, CD16 (FcγRIII-A), FCγRI (CD64), FCγRII (CD32), FCγRIII, FcRn, Fcα, or Fcε.
The intermediate of claim 1, wherein the subpopulation of the wild type NK-92 cells or the modified NK-92 cells the NK-92 cells comprises NK-92-CD16, NK-92-CD16-γ, or NK-92-CD16-ζ.
The intermediate of claim 1, wherein the subpopulation of the wild type NK-92 cells or the modified NK-92 cells expresses IL-2, an IL-2 receptor, IL-15, an IL-15 receptor, IL-18, an IL-18 receptor, IL-21, and/or an IL-21 receptor.
A method of producing a cell-based product, comprising:
- growing a plurality of NK-92 cells in a culture medium comprising a cytokine;
- wherein the NK-92 cells are a subpopulation of wild type NK-92 cells or modified NK-92 cells;
- wherein the subpopulation of wild type NK-92 cells or modified NK-92 cells is grown under conditions and for a time sufficient to produce cytotoxic exosomes;
- and
- removing at least some of the culture medium containing the exosomes and/or microvesicles from the subpopulation of wild type NK-92 cells or modified NK-92 cells in the culture medium.
The method of claim 8, wherein the cytokine is IL-2.
The method of claim 8, wherein the medium is a serum-free medium.
The method of claim 8, wherein the medium is supplemented with L-asparagine, L-glutamine, L-serine, interferon gamma, and/or IL-15.
The method of claim 8, wherein the subpopulation of the wild type NK-92 cells or the modified NK-92 cells express an Fc receptor selected from the group consisting of an Fcγ receptor, CD16 (FcγRIII-A), FCγRI (CD64), FCγRII (CD32), FCγRIII, FcRn, Fcα, or Fcε.
The method of claim 8, wherein the subpopulation of the wild type NK-92 cells or the modified NK-92 cells the NK-92 cells comprise NK-92-CD16, NK-92-CD16-γ, or NK-92-CD16-ζ.
The method of claim 8, wherein the subpopulation of the wild type NK-92 cells or the modified NK-92 cells expresses IL-2, an IL-2 receptor, IL-15, an IL-15 receptor, IL-18, an IL-18 receptor, IL-21, and/or an IL-21 receptor.
A cell-based method of treating cancer, comprising:
- administering to a patient in need thereof a composition that comprises a plurality of NK-92 cells and cytotoxic exosomes and/or microvesicles generated from the NK-92 cells;
- wherein the NK-92 cells are a subpopulation of wild type NK-92 cells or modified NK-92 cells;
- wherein the subpopulation of wild type NK-92 cells or modified NK-92 cells were grown under conditions and for a time sufficient to produce the cytotoxic exosomes.
Dependencies are inferred from the claim text.